Saccharomyces boulardii CNCM I-745 and smectite treatment for pediatric acute gastroenteritis in China: a systematic review and meta-analysis
Abstract
Introduction Pediatric acute gastroenteritis (PAGE) is a common cause of morbidity and mortality, especially among children under 5 years of age. Standard treatments typically include rehydration therapy, dietary modifications, antimicrobials, and adjunctive treatments with smectite or specific probiotics. The efficacy of adding Saccharomyces boulardii to standard treatments, including regimens that already incorporate smectites, remains not well known. Most trials evaluating this combination have been published in Chinese, which has limited global awareness of this type of treatment. Aim This study aimed to meta-analytically examine whether the addition of S. boulardii CNCM I-745 to smectite is more effective in treating PAGE than smectite alone. Methods Systematic searches were conducted in PubMed, Google Scholar, China National Knowledge Infrastructure, and the China Biology Medicine database up to 20 February 2025 receiving smectites. Eligible studies were randomized controlled trials conducted in China that compared S. boulardii CNCM I-745 with controls in children with PAGE receiving smectites, with no language restrictions. Data were independently extracted using standardized forms, including outcomes related to PAGE (cured, duration of PAGE, length of hospitalization, and immune markers) and potential confounding variables (dose, disease etiology). Results Of 57 included trials (5,767 participants), S. boulardii CNCM I-745 significantly improved the cure rate (RR =…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 5,767 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.